Jefremow A, Neurath M (2021)
Publication Type: Journal article, Review article
Publication year: 2021
Article Number: 101763
DOI: 10.1016/j.bpg.2021.101763
The human abdomen harbors organs that the host's immune system can attack easily. This immunological storm front leads to diseases like Crohn's Disease, Ulcerative Colitis or Autoimmune Hepatitis. Serious symptoms like pain, diarrhea, fatigue, or malnutrition accompany these diseases. Moreover, many patients have an increased risk for developing special kind of malignancies and some autoimmune disease can show a high mortality. The key to treat them consists of a deep understanding of their pathophysiology. In vitro and especially in vivo basic research laid the foundation for our increasing knowledge about it during the past years. This enabled the development of new therapeutic approaches that interact directly with cytokines or immune cells instead of building the treatment on a total immunosuppression. Different kind of antibodies, kinase inhibitors, and regulatory T cells build the base for these approaches. This review shows new therapeutical approaches in gastrointestinal autoimmune diseases in context to their pathophysiological basis.
APA:
Jefremow, A., & Neurath, M. (2021). New agents for immunosuppression. Best Practice & Research in Clinical Gastroenterology. https://doi.org/10.1016/j.bpg.2021.101763
MLA:
Jefremow, André, and Markus Neurath. "New agents for immunosuppression." Best Practice & Research in Clinical Gastroenterology (2021).
BibTeX: Download